Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Climb Bio, Inc. - Common Stock (NQ:CLYM)

2.419 +0.039 (+1.62%)
Streaming Delayed Price Updated: 12:56 PM EDT, Sep 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Climb Bio, Inc. - Common Stock

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
From Climb Bio, Inc.
Via GlobeNewswire
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at Upcoming September 2025 Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors 
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to be Added to the Nasdaq Biotechnology Index
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Host Virtual Investor Event on October 15, 2024
From Climb Bio, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.